OPKO Health Q1 loss per share of $0.01, beating estimates, while revenue decreased to $182.2M.
Biotech firm OPKO Health reported a Q1 loss per share of $0.01, beating analyst estimates of $0.09, while revenue was down to $182.2M from $184.7M in the previous year. The company has a market cap of $1.05B and a PE ratio of -4.29. Insiders have been selling stock, and analysts have varied opinions, with some rating OPKO Health a "buy" and others a "sell." OPKO Health operates in diagnostics and pharmaceuticals businesses in the US and internationally.
August 10, 2024
4 Articles